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Abstract
Recent studies have indicated that traditional Chinese medicines (CMs) and their active
compounds play an important  role  in liver  cancer treatment by preventing tumor
formation, inhibiting tumor growth, metastasis and recurrence as well as improving the
quality of life and reducing side effects of radiotherapy and chemotherapy. Mechanism
studies have proved the advantage of multicomponent, multitarget and multipathway
combinational regulation by CMs in liver cancer treatment. This chapter emphatically
introduces the molecular mechanisms underlying liver cancer treatment by CMs. In
addition, we also put forward discussion on existing obstacles and prospect of the future
development on liver cancer treatment using CMs, in terms of providing a comprehen‐
sive understanding of action of CMs in liver cancer treatment.
Keywords: TCM, Chinese medicines, Chinese herbal medicines, Anticancer, Antime‐
tastasis, Antiangiogenesis, adjuvant therapy, complementary, alternative treatment
1. Introduction
Primary liver cancer is a serious disease threatening human health. It was the sixth most
frequent cancer, and the second leading cause of cancer death worldwide according to the
reports from the International Liver Cancer Association in 2014 [1]. The most common type
of liver cancer is hepatocellular carcinoma (HCC), which is originated from hepatocyte. Other
types  of  liver  cancer,  such  as  hepatoblastoma  and  intrahepatic  cholangiocarcinoma,  are
relatively uncommon. Recognized risk factors for liver cancer include viral hepatitis B or C
infection, obesity and alcohol abuse. In developing countries such as African countries and
China, Hepatitis B or C is the major cause of liver cancer, whereas in developed countries such
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as the European Union and United States, the predominant cause of liver cancer is cirrhosis
caused by alcohol abuse or obesity [2]. In addition, inherited factor may also increase the risk
of liver cancer. Recent studies have found that some patients developed liver cancer with
inherited susceptible genes from their parents [3]. Usually, liver cancer has no symptoms at
the early stages; with the tumor progression, symptoms such as yellow skin, abdominal pain,
abdominal mass, nausea or liver dysfunction appear and rapidly deteriorate. Generally, the
prognosis of liver cancer is poor, because only 10–20% patients with early detection can receive
curative resection surgery. In addition, surgical resection is unavailable for cirrhotic patients
as increased risk of fatal complications may occur during resection on cirrhotic livers [4]. Other
conventional cancer treatment options such as radiation and chemotherapy are not routinely
used for liver cancer as the liver is chemotherapy‐refractory and not tolerant to radiation [5,
6]. In recent decades, several novel targeted therapies have been developed for liver cancer
treatment. The National Comprehensive Cancer Network (NCCN) guidelines recommend
sorafenib as the standard frontline therapy for patients with unresectable HCC but with well‐
preserved liver function [7, 8]. Other locoregional or adjuvant therapies such as the percuta‐
neous ablation (ethanol injection and radiofrequency ablation),  intra‐arterial  radiolabeled
lipiodol,  intra‐arterial  chemotherapy,  transarterial  chemoembolization (TACE),  interferon,
adoptive immunotherapy and complementary and alternative medicine are recommended for
providing  opportunity  for  liver  transplantation  or  extending  disease‐free  survival  and
improving survival quality. For patients who are diagnosed with early stage liver cancer, the
5‐year survival rate is about 31%. If the tumor has invaded to the surrounding organs or lymph
nodes, the 5‐year survival rate will decrease to 11%. If the cancer has metastasized to distant
organs, the 5‐year survival rate is only 3% [9].
Traditional Chinese medicine (TCM) is one of the most popular complementary and alternative
medicine in cancer patients worldwide. In China, TCM is based on the foundation of about
2500 years of folk medical practice, which have been covered by the National Health Insurance
Program and supported by the government in both Mainland of China and Taiwan. Different
from the western medicines that are based on modern human anatomy and pathology, TCM
is mainly focused on the identification of functional entities. In the view of TCM, health is
based on the harmonious interaction of the internal functional entities and the external
environment. The primary functional entities used by TCM include gas (Qi), blood (Xie),
internal organs (Zang‐fu) and the meridians (Jing‐luo) that are main channels of communica‐
tion of Qi and Xie in the body and link Zang‐Fu with the superficial areas of the body [10, 11].
There are various forms of TCM, which have been used for cancer patients, such as the herbal
remedies, acupuncture, moxibustion, breathing exercise and dietary therapy. These therapies
may have potential in improving the overall survival in cancer patients and the survival quality.
2. The understanding of liver cancer in traditional Chinese medicine
In TCM, liver cancer is associated with the presence of an “abdominal mass” called “zheng
jia” . “Zheng”  means fixed mass in the abdomen with fixed pain, while “Jia” 
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refers to abdominal mass occurs intermittently with no fixed pain. According to TCM litera‐
ture, the symptoms of liver cancer include abdominal distention, jaundice, abdominal fullness
and oppression. Those symptoms can be concluded as “Jiju” ( ), which means syndromes
caused by abdominal lump with pain or swelling. In TCM, the causes of liver cancer can be
divided into internal factors and external factors. The internal factors include individual
congenital constitution and emotional conditions. The emotions are considered as the major
internal causes of liver cancer in TCM. Emotions are regarded as internal, normal, physiolog‐
ical response to stimulus from the external factors. The negative emotions with high intensity
and prolonged duration may cause serious damage to the internal organs and influence the
healthy condition of the whole body. External factors include unhealthy dietary habits and
lifestyle such as alcohol beverage and contaminated food or over exhaustion. These factors can
lead to spleen and body disharmony. Other external factors such as the environment also play
an important role in the process of tumorigenesis. For example, the wet climate is considered
as an induction factor for liver cancer in TCM. Both internal and external factors may cause
stagnation of qi, spleen deficiency and the accumulation of dampness, which can eventually
lead to liver cancer.
3. The role of Chinese medicines and their active compounds in liver
cancer treatment
3.1. Chinese medicines and their active compounds for preventing liver cancer
From a TCM point of view, a good doctor should prevent and cure potential disease in the
initiating stage. “Treating before getting illness” is one of the preponderant thoughts of TCM
in dealing with disease and health. It is important to prevent the occurrence of liver cancer by
keeping healthy diet and lifestyle according to the TCM theories. As we have discussed earlier,
spleen deficiency may cause the occurrence of liver cancer. Symptoms such as ascites and
abdominal distention are all related to spleen deficiency. According to the relationship among
the TCM five internal organs (heart, liver, spleen, lungs and kidneys), the spleen and the liver
can influence on each other. Therefore, spleen deficiency can also restrict the liver function. In
order to strengthen spleen health and protect liver function, people should avoid taking too
much spicy and “cold” food such as pepper, green beans and cold water. Alcohol beverage
can also induce spleen deficiency by aggravating the dampness in the body. But moderate
drinking are beneficial for preventing liver diseases such as liver cancer according to TCM
theories [12].
Many Chinese medicines (CMs) and its active compounds are effective in reducing inflam‐
mation as confirmed by modern science [13, 14]. Recent studies have demonstrated that
inflammation is a major stimulus for hepatic carcinogenesis and some CMs may prevent liver
cancer by inhibiting inflammation in liver. Xiao Chai Hu Tang (XCHT) is an herbal medicine
formula used in some Asian countries for treating chronic viral liver diseases. According to
the TCM theories, XCHT can modulate Qi activity and balance between Yin and Yang. Recent
studies found that XCHT can prevent chronic hepatitis C‐related liver cancer by suppressing
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inflammation and inhibiting fibrosis in the liver [15]. Shi Quan Da Bu Tang (SQDBT) is a classic
TCM herbal diet formula that was documented in the “Tai Ping Imperial Grace Formulary” in
Song dynasty. In TCM, SQDBT were used to regulate Qi and treat Yang deficiency. Modern
scientific research show that SQDBT can relieve chronic viral liver diseases by reducing
inflammatory processes and controlling serum alanine transaminase (ALT) levels, thus it may
prevent liver cancer development [16]. Other TCM herbal extracts or isolates such as the Salvia
Miltiorrhiza extracts, Schisandra chinensis extracts, silymarin, glycyrrhizin, baicalein and
baicalin may prevent liver cancer by relieving chronic liver diseases associated hepatic steatosis
and fibrosis [17–21].
3.2. Chinese medicines and their active compounds for inhibiting liver cancer development
Invigorating Qi and strengthening the spleen; relieving Qi stagnancy in liver, clearing heat and
detoxifying, activating blood circulation to dissipate blood stasis, supplementing Qi and
nourishing yin are the main principles in treating primary liver cancer with TCM. Inhibiting
tumor growth, suppressing metastasis and preventing recurrence with TCM is the key to
restrain liver cancer development. According to a large‐scale cohort study in Taiwan, Jia Wei
Xiao Yao San (JWXYS) and Chai Hu Shu Gan Tang (CHSGT) are the most common TCM
prescriptions for liver cancer treatment. These TCM formulae can significantly inhibit tumor
development and improve survival in patients with primary liver cancer [22]. JWXYS are used
for invigorating the spleen and nourishing blood, it is effective for relieving Qi stagnancy in
liver. Besides its antihepatoma effects, JWXYS can also inhibit colon cancer and breast cancer
[23, 24]. CHSGT are also used for dispersing the Qi stagnancy in liver. Different from the JWXYS
that focuses on invigorating the spleen, CHSGT is mainly applied for activating Qi movement
and relieving pain. Both of these formulae have been safely used in liver cancer treatment for
patients in China, Taiwan and Hong Kong, with few side effects being reported. Some
pharmacological studies also revealed that a lot of CMs extracts or isolates could inhibit liver
cancer growth or metastasis both in vitro and in vivo. This includes but not limited to Coptidis
Rhizome extracts, Radix Bupleuri extracts, Radix Salvia Miltiorrhiza extracts, silymarin,
berberine, Wogonin, bufalin and curcumin [25–28].
3.3. Chinese medicines and their active compounds for improving the quality of life and
reducing the side effects of conventional therapy in liver cancer patients
As most of the liver cancer patients are diagnosed with late‐stage cancer, only 20% patients
may have the chance to receive curative treatment. In this case, improving the quality of life
and reducing the side effects of conventional therapy are very important for liver cancer
patients. The common side‐effects of conventional therapies, such as nausea, vomiting, fever,
abdominal pain, loss of appetite, alopecia and myelosuppression may lead to noncompliance
of treatment and thus affect treatment outcomes and reduce the quality of life. According to a
series of randomized clinical trials, CMs are effective in extending survival time, improving
quality of life, and reducing side effects of conventional therapies for liver cancer patients [29].
For example, Ophiopogonis Radix and Galli Gigerii Endothelium Corneum (Ji Nei Jing) are
most commonly used CMs for appetite improvement; Astragali Radix is widely used for
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alleviating fatigue; Artemisiae Scopariae Herba is recommended for abating jaundice;
Toosendan Fructus and Corydalis Rhizoma are effective in relieving abdominal pain; Peri‐
carpium Arecae, Polyporus, Poria can be used to treat ascites [26].
4. The molecular mechanism on liver cancer treatment by Chinese
medicines and their active compounds
4.1. Traditional Chinese medicines and its active compounds for inhibiting the proliferation
and inducing cell death in liver cancer cells
Jie Du Xiao Zheng Yin (JDXZY) is a typical TCM formula for liver cancer treatment. Recent
studies have found that JDXZY can suppress the proliferation of liver cancer cells in a dose‐
and time‐dependent manner [30]. In vivo studies also confirmed that JDXZY could increase the
tumor apoptotic index and reduce tumor size in nude mice. Mechanism studies showed that
JDXZY may induce human hepatoma HepG2 cell apoptosis by mitochondrial‐related pathway.
Treatment with JDXZY can activate caspase‐9 and caspase‐3 as well as up‐regulate the ratio of
Bax/Bcl‐2, which may partially demonstrate its antihepatoma effects. In addition, another
study also found that JDXZY could inhibit the proliferation of HepG2 cells by arresting the
cell cycle at the G0/G1 phase [31].
Bufalin is a digoxin‐like agent isolated from Chansu which is a precious CMs extracted from
parotoid glands of toads. Previous studies found that bufalin exhibited significant anticancer
activities in many cancer cell lines in vitro and in vivo. A recent research showed that bufalin
can suppress AKT‐related signaling pathway in HepG2 and HCCLM3 cell lines. After bufalin
treatment, the proliferation‐related proteins in AKT/GSK3beta/beta‐catenin/E‐cadherin‐
signaling pathway were significantly inhibited [32]. Thus, bufalin may be a potential anti‐
hepatoma agent by inhibiting the proliferation of cancer cell.
Gekko swinhonis Guenther also called ShouGong in TCM; it was a widely used anticancer drug
in China for hundreds of years. Modern science has demonstrated that one of the major active
components in Gekko swinhonis Guenther is sulfated polysaccharide–protein complex (GSPP).
Previous studies showed that GSPP can suppress the proliferation of liver cancer cells and
arrest the cell cycle in SMMC‐7721 cells with little direct toxicity [33]. In addition, Gepsin, the
monomeric protein in GSPP also showed strong inhibition on the proliferation of hepatocar‐
cinoma Bel‐7402 cells [34].
Many researches have revealed the strong anticancer activity of berberine. The protective
effects of berberine on liver diseases including liver cancer have been widely studied by our
groups. The quaternary ammonium salt derived from Coptidis Rhizome (Huanglian in TCM)
can induce both autophagy and apoptosis in hepatocellular carcinoma cells (HCC). Further
mechanisms studies demonstrated that berberine could induce mitochondrial apoptotic
signaling pathway in MHCC97‐L and HepG2 cells via upregulating Bax expression. Further‐
more, berberine could also induce autophagic cell death in HCC cells through inhibiting the
activity of Akt and activating the p38 MAPK‐signaling pathway [35].
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4.2. Chinese medicines and their active compounds for inducing liver cancer cells
differentiation
Panaxydol is one of the bioactive components in Panax Notoginseng (Sanqi in TCM). Panax
Notoginseng is a famous hemostatic in TCM and it can also relieve other blood disorders, such
as blood stasis or blood deficiency. Recent studies have shown that the panaxydol could induce
cell differentiation in human HCC cell lines SMMC‐7721 [36]. Ultrastructure morphology
observation confirmed that there have obvious cell morphologic changes after panaxydol
treatment. The activity of several differentiation related proteins such as alkaline phosphatase
and albumin were increased, while AFP activity was significantly decreased after panaxydol
treatment. These results showed that panaxydol may be a potential antihepatoma agent by
inducing tumor cell differentiation.
Gepsin can also inhibit liver cancer development by inducing cancer cells differentiation.
Studies showed that after gepsin treatment, the HCC cell line Bel‐7402 presents ultrastructural
morphology of differentiation. Western blot results revealed that the differentiation related
proteins such as the AFP protein secretion significantly decreased, while ALB protein expres‐
sion was obviously up‐regulated on gepsin‐treated cancer cells [34].
Ginseng is one of the most widely used herbs in TCM for thousands of years. Ginsenosides
are the main bio‐active components in Ginseng. There are many reports verified the anticancer
effect of ginsenosides in vitro and in vivo. For example, ginsenosides‐Rh2 (G‐Rh2) can inhibit
the proliferation of SMMC‐7721 cells as well as induce the mature and normality of cell
ultrastructure morphology. The expression of AFP, gamma‐GT and heat‐resistant ALP were
also significantly decreased after 10 mg/ml G‐Rh2 treatment [37].
4.3. Chinese medicines and their active compounds for averting the invasion and metastasis
of liver cancer cells
Ardipusilloside I is a triterpene‐saponin separated from the TCM herbs Ardisia pusilla A. DC.
Recent studies have revealed its anticancer effects through inhibition invasion and metastasis
of HCC cells [38]. Both in vitro and in vivo studies demonstrated that Ardipusilloside I may
suppress migration of HCC cells partially by decreasing the expression of the metalloprotei‐
nase (MMP)‐2 and MMP‐9 proteins. In addition, Ardipusilloside I can activate Rac1 protein
and further induce E‐cadherin which may result in inhibition of cancer cells migration.
As we have discussed earlier, GSPP and its monomeric protein gepsin are effective in inhibiting
the proliferation of HCC cells. Recent studies found that GSPP was also effective in suppressing
the migration of HCC cells [33]. GSPP treatment remarkably decreased the concentration of
intracellular calcium. Many studies have demonstrated that low intracellular calcium concen‐
tration is associated with reduced cancer migration. GSPP treatment could remarkably
decrease the concentration of intracellular calcium. Thus, the antimigration effect by GSPP
may be partially a consequence of downregulation of intracellular calcium concentration
together with an upregulation of actin filaments polymerization in HCC cells.
The hepatic protective effects of Radix Salviae have been verified through its extensive use in
TCM. Recent studies also found that aqueous extracts of Radix Salviae can inhibit the devel‐
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opment of liver cancer by suppressing the metastasis and recurrence in animal models [21].
In vitro study showed that Radix Salviae treatment significantly decreased the expression of
Intercellular Adhesion Molecule 1(ICAM‐1) in SMMC‐7721 cells. In addition, it could suppress
the invasion of SMMC‐7721 cell and make the fibronectin‐attached cells exfoliated. The cell
adhesion ability of HCC‐HCC, HCC‐lymphocyte and HCC‐endothelial cell also decreased
after Radix Salviae treatment. The tumor xenograft mice model also confirmed the antimeta‐
stasis effects of Radix Salviae on posthepatectomy liver cancer in vivo.
Curcumin, a polyphenol isolated from the rhizome of Curcuma longa (Jiang in TCM) has
potential anti‐cancer effects in many types of cancers. However, due to its poor aqueous
solubility, the clinical application of curcumin has been limited. A recent study has used the
polymeric nanoparticle formulation of curcumin to improve its solubility as well as anticancer
activity [39]. The results showed that when used as a combination with sorafenib, the modified
curcumin can suppress the proliferation and invasion of HCC cells in vitro. Furthermore, in
vivo study also found curcumin could inhibit liver cancer growth and lung metastases.
Mechanisms study found curcumin and sorafenib synergistically inhibited the expression of
MMP9 by down‐regulating NF‐kappaB/p65‐signaling pathway. Taken together, the polymeric
nanoparticle formulation of curcumin may exhibit antitumor activity by inhibiting liver cancer
metastasis.
4.4. Chinese medicines and their active compounds for inhibiting angiogenesis in liver
cancer treatment
Angiogenesis is a physiological process during which new blood vessels are produced and
developed based on the original vessels. As angiogenesis plays a crucial role in tumor growth
and metastasis, the novel antitumor therapies targeting angiogenesis may provide new hopes
for cancer treatment. Livistona Chinensis seeds (EELC) have been used for centuries in TCM
for cancer treatment. HCC xenograft mice model confirmed that EELC can inhibit tumor
angiogenesis through the Notch‐signaling pathway [40]. After EELC treatment, in vivo results
showed remarkable decrease in intratumoral microvessel density (MVD) in the HCC xenograft
mice tumors. In addition, the angiogenesis‐related proteins such as the VEGF‐A and VEGFR‐
2 were significantly decreased after EELC treatment. The mechanism study demonstrated that
the antiangiogenesis effect was related with the inhibition of the Notch pathway as the
expression of Notch, Dll4 and Jagged1 were down regulated according to the real‐time
polymerase chain reaction (RT‐PCR) results.
Yang Zheng Xiao Ji (YZXJ) is a commercial TCM product for supplementary treatment of
advanced liver cancer. Some clinical trials indicated that YZXJ may improve the curative effect
of interventional chemotherapy for advanced liver cancer patients. In vitro studies showed that
YZXJ can inhibit the matrigel‐based sandwich tubule formation and cell migration. Western
blot results confirmed that inhibition of the activation of focal adhesion kinase may at least in
part confer the YZXJ‐induced inhibition of cell migration and tube formation [41]. These results
indicated that YZXJ could be a potential antihepatoma TCM product via suppressing tumor
angiogenesis.
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Asparagus polysaccharide, the bioactive derivate from Asparagus, is a common TCM herbal
diet that may exhibit anticancer activity according to previous researches. One study has
explored the adjunctive effects of asparagus polysaccharide in liver cancer chemotherapy [42].
Their results showed that asparagus polysaccharide significantly suppressed liver cancer
growth in combination with transcatheter arterial chemoembolization (TACE) therapy in
orthotopic HCC rat model. Tumor angiogenesis may be the major target for asparagine
gelatinous in liver cancer treatment. Several angiogenesis markers such as CD34 and VEGF
significantly decreased after asparagine gelatinous treatment. The expression of MVD markers
also remarkably reduced in asparagus polysaccharide treated liver tumors. These results
suggested that asparagus polysaccharide with TACE could apparently inhibit the tumor
angiogenesis in vivo; asparagus polysaccharide might be a potential adjunvant therapy for
TACE in treating liver cancer.
4.5. Chinese medicines and their active compounds for enhancing immunological function
in liver cancer patient
The TCM formula Songyou Yin (SYY) was developed by Professor Zhao‐You Tang for liver
cancer treatment. Recent studies have found that the antimetastasis and anti‐recurrence effects
by SYY may be correlated with its immunomodulation activity. SYY can significantly extend
survival and inhibit the tumor growth and metastasis in tumor‐burdened mice. SYY remark‐
ably increased the ratio of CD4/CD8 in peripheral blood and decreased the serum TGF‐beta1
activity as well as the percentage of Treg cells both in spleen and peripheral blood. Thus, the
TCM product SYY may strengthen the immunity of liver cancer patient and prevent tumor
recurrence [43].
Mylabris mixture is a popular anticancer TCM formula which mainly consists of the Mylabris
extracts, Tangerine Peel and Millet Sprout. Recent studies found that Mylabris mixture could
obviously suppress the growth of liver cancer H22 cells by improving the immunological
function in mice model [44]. After Mylabris mixture treatment, the stimulation index of T‐
lymphocyte transformation and proportion of NK cells were apparently increased. The
subpopulation percentage of T lymphocytes also significantly increased after Mylabris mixture
treatment. Up‐regulation on the secretion of interferon‐gamma and interleukin‐4 by T
lymphocytes also confirmed the immunoloregulation effects by Mylabris mixture.
A recent study has explored the immunoloregulation effects of ultrasound‐guided intratu‐
moral injection of TCM formula “Star‐99” in HCC in mice model. Star‐99 can improve the
cellular immunity and induce HCC cell apoptosis by increasing the level of plasma IL‐2 and
TNF‐alpha. The cytokines IL‐2 can be considered as an immunological response modifier. It
can improve the activity of lymphocyte and the anti‐tumor effects of NK, CTL and LAK cells
as well as cytokine secretion. In addition, another experiment also found that many lympho‐
cytes can be observed in the tumor tissues after the Star‐99 treatment [45]. The electron
microscope results observed that the microvilli on the surface of the lymphocytes attacked the
cancer cells. The membrane of tumor cell in contact with the sensitized T lymphocyte became
broken with the organelle and the nucleus dissolved and the vacuolation of the cytoplasm as
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well. This phenomenon further illustrate that the Star‐99 could stimulate and induce the
cellular immunity function of the organism.
Previous studies revealed the TCM herbal product Kanglaite (KLT) which mainly consists of
Jobstears Seed oil exhibits anticancer and immunoregulation activities. According to a clinical
study, KLT treatment can improve the immunological function via increasing the proportion
of T cells and NK cells in the blood of HCC patients [46]. In vivo study in tumor‐bearing mice
showed that KLT enhanced the immune system by increasing the secretion of several cytokines
such as the IFN‐gamma and IL‐2, and up‐regulate the proportion of CD4+ T cells in mice. These
events further improved the killing activity of NK cells and CD8+ T cells against the HepG2
cells. KLT treatment also up‐regulate the mRNA level of some NF‐kappaB responsive genes
in CD4+ cells. In conclusion, KLT may have immunomodulatory activity at least partially
through the activating of NF‐kappaB mediated gene transcription in CD4+ T cells.
4.6. Chinese medicines and their active compounds for reversing drug resistance in liver
cancer treatment
Astragaloside is a saponin isolated from Radix Astragali, one of the popular TCM herbs.
Astragaloside has been reported to be an effective agent in reversing multidrug resistance
(MDR) of cancer treatment. A recent study found that astragaloside can modulate the ex‐
pression of P‐glycoprotein in human hepatic cancer cells Bel‐7402 and reverse 5‐fluoroura‐
cil resistance in chemotherapy. As P‐glycoprotein majorly is responsible for the drug
efflux in cancer treatment, the down‐regulation of P‐glycoprotein will inhibit P‐glycopro‐
tein‐mediated drug efflux and improve the efficacy of chemotherapies [47]. Thus, astraga‐
loside may be a potential anticancer drug for reversing drug resistance in liver cancer
treatment.
Polyphyllin D is a saponin derived from a TCM herb Paris Polyphylla. The herb of Paris
Polyphylla has been used for liver cancer treatment in China for thousands years. Previous
study showed that polyphyllin D can induce apoptosis in multi‐drug resistant HepG2 cells
[48]. Further mechanism study demonstrated that polyphyllin D may elicit mitochondrial
fragmentation in HCC cells. When treating polyphyllin D directly to the isolated mito‐
chondria, the mitochondria exhibited strong swelling with deep transmembrane depolari‐
zation. In addition, significant apoptosis‐inducing factor release could be observed from
the multidrug‐resistant HepG2 cells. These results suggest that polyphyllin D may be a
potential anti‐cancer agent targeting drug resistance in HCC cells by inducing mitochon‐
drial damage.
Piper betel leaves (PBL) are enriched with medication properties in TCM for many centu‐
ries. Modern researches have proven that PBL has antioxidation activity and may inhibit
gene mutation. Recent study has found that PBL extract can inhibit total Glutathione S‐
transferase (GST) and alpha class of GST (GSTA) in HepG2 cells [49]. Further study showed
PBL could enhance the sensitivity of HCC cells to chemotherapy. The results revealed that
the cytotoxicity of cisplatin was apparently increased in cell with PBL treatment, with the
mechanism related to the inhibition of multidrug resistance protein 2. These results indicat‐
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ed that PBL extract may reduce drug resistance and improve the efficacy of chemotherapy
in liver cancer treatment.
5. Future prospect of liver cancer treatment by Chinese medicines and their
active compounds
CMs and its active compounds have a long history for anticancer treatment in China. In recent
decades, many TCM formulae, herbal extracts or isolates have been developed to treat liver
cancer, especially for patients with advanced‐stage liver cancer. According to both clinical
studies and basic researches, CMs have less toxicity and exhibit multitarget anticancer activity.
In China, the antihepatoma effects of several TCM products have been verified by clinical trials,
such as the Songyou Yin and Kanglaite injection. Many studies have proven that CMs had
beneficial effects in relieving fatigue and pain, preventing respiratory tract infections and
alleviating gastrointestinal symptoms in liver cancer patients.
However, there are also some problems with CMs in current cancer treatment that should be
considered seriously. First of all, most of the CMs are extracted from plants or animals, their
pharmacological active components are still unknown CMs. Second, the adverse effects,
contraindications and corresponding clinical data of CMs are rarely indicated by TCM doctors
or CMs manufacturers. Third, the frequent occurrence of fatal accidents such as allergy and
phlebitis has been observed during TCM treatment especially in TCM injection treatment.
Finally, although there are many clinical trials on CMs for liver cancer treatment, none of them
were large multicenter trials with strict and standard criteria CMs. In this case, it is difficult to
give an accurate conclusion about the effects of CMs for liver cancer treatment when conduct‐
ing a meta‐analysis. Therefore, large‐scale multicenter clinical trials with strict and standard
criteria are urgently needed for the development of TCM in liver cancer treatment. According
to the previous studies, combination of CMs and its active compounds with surgery, TACE or
chemotherapy may protect liver function, enhance the patients’ immune response, and reduce
the side effects and complications of conventional therapy as well as prolong lifespan. With
the rapid development of modern scientific research, the combination therapy with TCM will
be definitely promising for future liver cancer treatment.
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